公开(公告)号：US11723953B2

公开(公告)日：2023-08-15

申请号：US17368464

申请日：2021-07-06

申请人： CSL Limited

发明人： Samuel Wright ,  Martin Imboden ,  Reinhard Bolli ,  Marcel Waelchli

IPC分类号： A61K38/17 ,  A61K9/00 ,  A61K9/127 ,  A61K31/56 ,  A61K31/685 ,  A61K45/06 ,  A61K31/575

CPC分类号： A61K38/1709 ,  A61K9/0019 ,  A61K9/1275 ,  A61K31/56 ,  A61K31/575 ,  A61K31/685 ,  A61K45/06 ,  A61K31/685 ,  A61K2300/00 ,  A61K31/56 ,  A61K2300/00 ,  A61K38/1709 ,  A61K2300/00

摘要： A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.

公开(公告)号：US10335457B2

公开(公告)日：2019-07-02

申请号：US15241895

申请日：2016-08-19

申请人： CSL Limited

发明人： Samuel Wright ,  Martin Imboden ,  Reinhard Bolli ,  Marcel Waelchli

IPC分类号： A61K9/00 ,  A61K31/56 ,  A61K38/17 ,  A61K45/06 ,  A61K9/127 ,  A61K31/575 ,  A61K31/685

摘要： A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.

公开(公告)号：US20220133852A1

公开(公告)日：2022-05-05

申请号：US17368464

申请日：2021-07-06

申请人： CSL Limited

发明人： Samuel Wright ,  Martin Imboden ,  Reinhard Bolli ,  Marcel Waelchli

IPC分类号： A61K38/17 ,  A61K9/00 ,  A61K9/127 ,  A61K31/56 ,  A61K31/685 ,  A61K45/06 ,  A61K31/575

摘要： A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.

公开(公告)号：US20200171126A1

公开(公告)日：2020-06-04

申请号：US16445937

申请日：2019-06-19

申请人： CSL LIMITED

发明人： Samuel Wright ,  Martin Imboden ,  Reinhard Bolli ,  Marcel Waelchli

IPC分类号： A61K38/17 ,  A61K9/00 ,  A61K9/127 ,  A61K31/56 ,  A61K31/685 ,  A61K45/06 ,  A61K31/575

摘要： A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.

公开(公告)号：US20170196935A1

公开(公告)日：2017-07-13

申请号：US15241895

申请日：2016-08-19

申请人： CSL Limited

发明人： Samuel Wright ,  Martin Imboden ,  Reinhard Bolli ,  Marcel Waelchli

IPC分类号： A61K38/17 ,  A61K31/575 ,  A61K31/685

CPC分类号： A61K38/1709 ,  A61K9/0019 ,  A61K9/1275 ,  A61K31/56 ,  A61K31/575 ,  A61K31/685 ,  A61K45/06 ,  A61K2300/00

摘要： A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.

公开(公告)号：US11058747B2

公开(公告)日：2021-07-13

申请号：US16445937

申请日：2019-06-19

申请人： CSL LIMITED

发明人： Samuel Wright ,  Martin Imboden ,  Reinhard Bolli ,  Marcel Waelchli

IPC分类号： A61K38/17 ,  A61K9/00 ,  A61K9/127 ,  A61K31/56 ,  A61K31/685 ,  A61K45/06 ,  A61K31/575

摘要： A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.

公开(公告)号：US09439946B2

公开(公告)日：2016-09-13

申请号：US14633880

申请日：2015-02-27

申请人： CSL Limited

发明人： Samuel Wright ,  Martin Imboden ,  Reinhard Bolli ,  Marcel Waelchli

IPC分类号： A61K38/17 ,  A61K9/00 ,  A61K9/127 ,  A61K31/56 ,  A61K31/685 ,  A61K45/06

CPC分类号： A61K38/1709 ,  A61K9/0019 ,  A61K9/1275 ,  A61K31/56 ,  A61K31/575 ,  A61K31/685 ,  A61K45/06 ,  A61K2300/00

摘要： A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.